Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer

References

• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• SugiuraSAndoYMinamiHAndoMSakaiSShimokataKPrognostic value of pleural effusion in patients with non-small cell lung cancerClin Cancer Res19973147509815536
   PubMed Web of Science ®Google Scholar
• AyantundeAAParsonsSLPattern and prognostic factors in patients with malignant ascites: a retrospective studyAnn Oncol200718594594917298959
   PubMed Web of Science ®Google Scholar
• ChenDLiXZhaoHThe efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusionIndian J Cancer201451Suppl 3e82e8525818740
   PubMed Web of Science ®Google Scholar
• TamiyaMTamiyaAYamadoriTPhase 2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusionMed Oncol201330367623925664
   PubMed Web of Science ®Google Scholar
• IshimotoOSaijoYNarumiKHigh level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancerOncology2002631707512187074
   PubMed Web of Science ®Google Scholar
• ChenDSongXZhangYKongLWangHYuJOptimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is moreFuture Oncol201814212131213829546764
   PubMed Web of Science ®Google Scholar
• KitamuraKKubotaKAndoMBevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusionCancer Chemother Pharmacol201371245746123178954
   PubMed Web of Science ®Google Scholar
• ChenDSongXShiFGreater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusionOncotarget2017821352623527127823984
   PubMedGoogle Scholar
• El-ShamiKElsaidAEl-KermYOpen-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascitesJ Clin Oncol20072518S9043
   Google Scholar
• BellatiFNapoletanoCRuscitoIComplete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature reviewInvest New Drugs201028688789419936983
   PubMed Web of Science ®Google Scholar
• HamiltonCAMaxwellGLChernofskyMRBernsteinSAFarleyJHRoseGSIntraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancerGynecol Oncol2008111353053218561992
   PubMed Web of Science ®Google Scholar
• WuYLLuSLuYResults of PROFILE 1029, a Phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancerJ Thorac Oncol20181310S155630721S155630724
   Web of Science ®Google Scholar
• Martínez-MoragónEAparicioJSanchisJMenéndezRCruz RogadoMSanchisFMalignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 casesRespiration19986521081139580921
   PubMed Web of Science ®Google Scholar
• HeffnerJEKleinJSRecent advances in the diagnosis and management of malignant pleural effusionsMayo Clin Proc200883223525018241636
   PubMed Web of Science ®Google Scholar
• RuizEAlemanCAlegreJSorianoTFernandez deSevillaTAngiogenic factors and angiogenesis inhibitorsin exudative pleural effusionsLung200518318519516078040
   PubMed Web of Science ®Google Scholar
• HamedEAEl-NoweihiAMMohamedAZMahmoudAMediatorsMVVasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusionsRespirology200491818614982607
   PubMed Web of Science ®Google Scholar
• JiaLDuYLiTDifferential expression of vascular endothelial growth factor-A, -C and -D for the diagnosis and prognosis of cancer patients with malignant effusionsOncol Lett201510266767426622551
   PubMed Web of Science ®Google Scholar
• ZhaoHLiXChenDIntraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trialMed Oncol201532229225609006
   PubMed Web of Science ®Google Scholar
• HsuLHHsuPCLiaoTLFengACChuNMKaoSHPleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort studyBMC Cancer201616146327411914
   PubMed Web of Science ®Google Scholar
• ThickettDRArmstrongLMillarABVascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusionsThorax199954870771010413724
   PubMed Web of Science ®Google Scholar
• GroveCSLeeYCVascular endothelial growth factor: the key mediator in pleural effusion formationCurr Opin Pulm Med20028429430112055392
   PubMed Web of Science ®Google Scholar
• RibeiroSCVargasFSAntonangeloLMonoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusionRespirology20091481188119319818055
   PubMed Web of Science ®Google Scholar
• OidaTMimatsuKKanoHPericardiocentesis with cisplatin for malignant pericardial effusion and tamponadeWorld J Gastroenterol201016674074420135723
   PubMed Web of Science ®Google Scholar
• JiangLLiPGongZEffective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatinAnticancer Res20163631313131826977031
   PubMed Web of Science ®Google Scholar
• ChenDZhangYShiFSustained response of malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung cancer patient: a case report and literature reviewOnco Targets Ther201582767277026491350
   PubMed Web of Science ®Google Scholar